Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer6 Nov 2026

334 Phase 1 trial of GC101, an IL2free autologous tumor-infiltrating lymphocyte (TIL) therapy, in recurrent high-grade glioma: safety and preliminary efficacy

Qing Lan¹
Ying Cheng²
Yanming Chen³
Huajun Jin⁴
Wenjia Zhuang⁴

4 affiliations

¹Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA
²4 Xi’an No.1 Hospital, Xi’an, Shaanxi Province, China
³The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
⁴2Shanghai Juncell Therapeutics Co., Ltd., Shanghai, China

Open at source PDF DOI Cite

352 Assessment of the Xiogenix Ares X20+ as an automated fill-finish solution for tumor-infiltrating lymphocyte therapy manufacturing
Chantale Bernatchez, Marie-Andree Forget, Donastas Sakellariou-Thompson +7
Journal for ImmunoTherapy of Cancer4 Nov 2026Peer-reviewedCC BYOncologyDOAJ
Tumour region identification guided scoring (TRIGS) and foundation model-based Tumour Infiltrating Lymphocyte scoring are prognostic for pathological complete response/event free survival in the triple negative patients in the PARTNER randomized controlled trial
P. C. Schouten, M. O. Irfan, Z. Kinsella +15
medRxiv15 Sep 2026PreprintCC BY-NDFull textGeneral medicinemedRxiv
BCL2A1 marks an early, less-exhausted CD8+ tumor-infiltrating lymphocyte state associated with PD-1 blockade response in NSCLC
Hoang Minh Quan Pham, Chia-Ling Chen, Po-Hao Feng +3
Frontiers in Immunology7 Oct 2026Peer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
Autologous Peripheral Blood-Derived Stem Cells Combined with Platelet-Rich Plasma is Associated With Clinical and Radiological Improvement in Anterior Cruciate Ligament Ruptures—Preliminary Clinical and MRI Findings in 47 Consecutive Patients
Patrick Weninger, Andreas Herbst, Veronika Pfafl-Weninger +1
Indian journal of orthopaedics28 Jul 2026Peer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
Peripheral Lymphocyte Subsets Predict Efficacy and Overall Survival in Gastric Cancer Patients Receiving Preoperative Chemotherapy: A Retrospective Cohort Study
Zirui Xue, Dan Liu, Zhaodong Sun +6
Cancer reports (Hoboken, N.J.)1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@article{lan2026phase,
  title = {{334 Phase 1 trial of GC101, an IL2free autologous tumor-infiltrating lymphocyte (TIL) therapy, in recurrent high-grade glioma: safety and preliminary efficacy}},
  author = {Qing Lan and Ying Cheng and Yanming Chen and Huajun Jin and Wenjia Zhuang},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0334},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0334},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 334 Phase 1 trial of GC101, an IL2free autologous tumor-infiltrating lymphocyte (TIL) therapy, in recurrent high-grade glioma: safety and preliminary efficacy
AU  - Qing Lan
AU  - Ying Cheng
AU  - Yanming Chen
AU  - Huajun Jin
AU  - Wenjia Zhuang
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0334
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0334
SN  - 2051-1426
ER  -

Related

Cite